Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05796375 · ClinicalTrials.gov registry record · Phase 2
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
A Phase 2 study of Non-muscle Invasive Bladder Cancer, sponsored by White River Junction Veterans Affairs Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 8
- Study locations
NCT05796375: Recruiting Phase 2 study of Non-muscle Invasive Bladder Cancer, sponsored by White River Junction Veterans Affairs Medical Center.
NCT05796375 is a Phase 2 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by White River Junction Veterans Affairs Medical Center. The registered enrollment target is 240 participants, above the 219-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (10% higher). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05796375, a Phase 2 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by White River Junction Veterans Affairs Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, complications, cancer recurrence or cancer progression when some cystoscopy procedures are replaced with urine testing.
Primary Outcome
Measuring change from baseline. Score range: 0-100. Lower score indicates higher quality of life.
Conditions Studied
Interventions
- PROCEDURE Cystoscopy
- DIAGNOSTIC_TEST Bladder EpiCheck urine test
- DIAGNOSTIC_TEST Xpert Bladder Cancer Monitor urine test
Study Locations (8)
Connecticut
- West Haven VA Medical Center - West Haven
Florida
- Bay Pines VA Healthcare System - Bay Pines
Massachusetts
- VA Boston Jamaica Plains Campus - West Roxbury
Missouri
- VA St.Louis Healthcare System - St Louis
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
South Carolina
- Medical University of South Carolina - Charleston
Texas
- UT Southwestern Medical Center - Dallas
Vermont
- White River Junction Veterans Healthcare System - White River Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
What NCT05796375 shows while recruiting
NCT05796375 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 219-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cystoscopy is the first listed.
NCT05796375 lists 8 locations in 8 states (Connecticut, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05796375 about?
NCT05796375 is a clinical study titled "Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance". The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary symptoms, discomfort, number of invasive procedures, anxiety, comp...
What is the current status of trial NCT05796375?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2023-11-17. Estimated completion is 2028-12-30.
What conditions does trial NCT05796375 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
What interventions are being tested in trial NCT05796375?
The interventions under investigation include: Cystoscopy (PROCEDURE), Bladder EpiCheck urine test (DIAGNOSTIC_TEST), Xpert Bladder Cancer Monitor urine test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05796375?
This trial is sponsored by White River Junction Veterans Affairs Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05796375 being conducted?
This trial has 8 study locations across Connecticut, Florida, Massachusetts, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05796375's enrollment target sits among peer trials
240 10th of 30 higher than 21 of 30 other Non-muscle Invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC
RECRUITING · Phase 2
-
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
COMPLETED · Phase 2
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI